An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy

Trial Profile

An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Risdiplam (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms Jewelfish
  • Sponsors Roche
  • Most Recent Events

    • 27 Apr 2018 Planned primary completion date changed from 5 Apr 2019 to 1 Dec 2020.
    • 23 Apr 2018 Planned End Date changed from 5 Apr 2019 to 1 Dec 2020.
    • 16 Apr 2018 According to the Genentech media release, data from this study will be presented at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top